# A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

> **NCT05403749** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 132 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** dose 1 IBI302
- **DRUG:** Aflibercept
- **BIOLOGICAL:** dose 2 IBI302

## Key facts

- **NCT ID:** NCT05403749
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-05-13
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403749, "A Study of Longer Interval of IVT IBI302 in Subjects With nAMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05403749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*